AZN vs GSK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GSK is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and GSK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and GSK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

GSK plc is a UK-headquartered global biopharma company, one of the largest by revenue, focused on preventing and treating disease through vaccines, specialty medicines, and general medicines. It reorganized in 2022 when it spun off its consumer health arm as Haleon, leaving GSK as a pure biopharma business. Its most durable franchises are vaccines, led by the shingles vaccine Shingrix and the newer RSV vaccine Arexvy, and HIV, which it manages largely through the ViiV Healthcare joint venture with a shift toward long-acting injectable regimens. It also has growing positions in respiratory, immunology and inflammation, and oncology.

Full GSK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
• GSK drivers: Vaccines franchise durability; HIV and long-acting injectables.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For GSK, the central risk is the patent cliff and pipeline dependence: maturing products face generic and biosimilar competition, and the longer-term case relies on newer launches replacing that revenue, which is never guaranteed in drug development.

Pick AZN if you believe its drivers more; GSK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and GSK guides.

AZN. Figures are approximate and tied to the asOf date; confirm live numbers before acting. AstraZeneca trades as a growth-oriented large-cap pharma, so its valuation reflects confidence in the pipeline delivering on the $80 billion 2030 goal more than any single current metric. A patent cliff early next decade means today's revenue base is not guaranteed to persist, so how you weigh future launches matters more than trailing multiples.

GSK. These figures are approximate, tied to the asOf date, and reported in a mix of pounds and dollars because GSK is a UK company trading as a US ADR, so verify live numbers before acting. GSK's lower multiple reflects slower growth and pipeline and litigation overhangs rather than a distressed balance sheet. The stock tends to behave like a value-and-income pharma holding, so the multiple matters less than whether new launches can offset patent expiries over time.

Headline figures (approximate, Jul 2026): AZN shows revenue (ttm) Around $60 billion; 2025 total revenue was about $58.7 billion, up roughly 9%, with Q1 2026 up about 8% at constant currency, growth drivers Oncology (Tagrisso, Imfinzi, Calquence, Enhertu, Lynparza), rare disease (Ultomiris, Soliris) and metabolic launches; company ambition of $80 billion revenue by 2030, margins/profitability Solidly profitable large-cap pharma; heavy, sustained R&D spending funds the pipeline that the 2030 target depends on, dividend Pays a regular dividend; recent yield roughly 2%, modest for the sector but backed by large, growing cash flows; GSK shows revenue (ttm) approximately £31 to £32 billion, with vaccines, HIV, and specialty medicines the main contributors, operating margin reported around the mid-to-high 20s percent on an adjusted basis, typical of large-cap pharma, eps adjusted earnings per share reported in roughly the mid-single-digit dollars per ADR; verify the latest figure live, market cap approximately $105 to $110 billion (ADR traded around the low $50s in early 2026).

AZN and GSK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AZN and GSK exposure against your real portfolio. It is not an investment adviser.